Home Neurological Disorders ALS

ALS

Most popular
Source: © iceteastock/Fotolia.com
ALS

Novel Research Model Offers Hope to ALS and MS Patients

ALS

Biogen, Ionis Launch $1B+ Expanded Neuro Drug Partnership, following Spinraza Success

ALS

Neuraltus Weighs Future of Lead Candidate NP001 after Failure in Phase...

Flex Pharma cites unspecified “oral tolerability concerns” in halting Phase II trials of FLX-787 in amyotrophic lateral sclerosis (ALS) and Charcot-Marie-Tooth (CMT). [© whitehoune / Fotolia]
ALS

Flex Pharma Axes 60% of Workforce, Explores Sale after Halting Phase...

ALS

Sangamo, Pfizer Partner on Gene Therapy for ALS, FTLD

Benitec Biopharma could generate up to $655 million-plus in payments from licensing its preclinical gene therapy for oculopharyngeal muscular dystrophy (OPMD; pictured)
ALS

Axovant Licenses Benitec Gene Therapy Candidates for OPMD, Neurological Disorders

The hnRNPA2 protein forms liquid droplets in a test tube
ALS

Proteomics Finding May Lead to Therapy Targeted at Cellular Pathway Linked...

ALS

CRISPR Human Knockout Screens Identify New Target for ALS

Source: Pixabay
ALS

CRISPR Screen Identifies Genetic Modifiers of ALS

The hnRNP A1B is expressed in the central nervous system and forms cytoplasmic aggregates in ALS patient neurons. [CRCHUM]
ALS

Hope for ALS Patients Comes from New Understanding of RNA Metabolism...

12Page 1 of 2

COVID-19 Candidates

Recently Featured

Copyright © 2020 Genetic Engineering & Biotechnology News. All Rights Reserved.
Scroll Up